Publications by authors named "A J Tipping"
Using a life tables approach with 2011-2017 claims data, we calculated lifetime risks of infection (CDI) beginning at age 18 years. The lifetime CDI risk rates were 32% in female patients insured by Medicaid, 10% in commercially insured male patients, and almost 40% in females with end-stage renal disease.
View Article and Find Full Text PDFArticle Synopsis
- * It analyzed Missouri Medicaid claims data from 2012 to 2021, finding that while the percentage of patients receiving MOUD after an overdose increased significantly, overall, only a small fraction (12.1%) received treatment.
- * Results indicated that receiving MOUD reduced the risk of repeat overdose by about 66%; individuals whose initial overdose was related to heroin or synthetic opioids were at an even higher risk but still benefited from MOUD treatment.
Affinity-optimized T cell receptors can enhance the potency of adoptive T cell therapy. Afamitresgene autoleucel (afami-cel) is a human leukocyte antigen-restricted autologous T cell therapy targeting melanoma-associated antigen A4 (MAGE-A4), a cancer/testis antigen expressed at varying levels in multiple solid tumors. We conducted a multicenter, dose-escalation, phase 1 trial in patients with relapsed/refractory metastatic solid tumors expressing MAGE-A4, including synovial sarcoma (SS), ovarian cancer and head and neck cancer ( NCT03132922 ).
View Article and Find Full Text PDFObjective: Few data are available to quantify the infection (CDI) burden in US adults depending on Medicaid insurance status; thus, we sought to contribute to this body of information.
Methods: Retrospective cohort study to identify adults with codes for CDI from 2011 to 2017 in MarketScan commercial and Medicaid databases (for those aged 25-64 years) and the CMS Medicare database (for those aged ≥65 years). CDI was categorized as healthcare-facility-associated (HCA-CDI) and community-associated CDI (CA-CDI).
Objective: To examine the association between state-mandated insurance coverage for infertility treatment in the United States and the utilization of and indication for preimplantation genetic testing.
Methods: This was a retrospective cohort study of 301,465 in vitro fertilization (IVF) cycles reported to the Society for Assisted Reproductive Technology between 2014 and 2016. Binomial logistic regression was performed to examine associations between state-mandated insurance coverage and preimplantation genetic testing use.